This case study provides real-world evidence of the clinical utility of CyPath Lung, which could support future commercial adoption. However, as a single case study, it does not represent a material business development or regulatory milestone.
Price Chart
Executive Summary
bioAffinity Technologies announced a new clinical case study demonstrating the use of its CyPath Lung diagnostic test to help avoid an unnecessary biopsy in a high-risk patient with a suspicious lung nodule. The test provided additional data supporting the physician's assessment that the nodule was inflammation rather than cancer, which was confirmed by follow-up imaging.
Key Facts
- Company issued a press release about a clinical case study involving its CyPath Lung diagnostic test
- The case study showed how the test helped a physician determine that a suspicious lung nodule was inflammation rather than cancer
- The patient avoided an unnecessary biopsy based on the test results
- The case study is presented as a single patient experience and does not establish generalized clinical utility
Financial Impact
No immediate financial impact disclosed
Risk Factors
- The case study is limited to a single patient and does not establish generalized clinical utility
- The company is still in early stages of commercialization with limited market penetration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016486 |
| Exhibit: ex99-1.htm | 0001493152-26-016486 |
| Document: 0001493152-26-016486-index-headers.html | 0001493152-26-016486 |
| Document: 0001493152-26-016486-index.html | 0001493152-26-016486 |
| Document: 0001493152-26-016486.txt | 0001493152-26-016486 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.2950 $0.1300 | ▼ −55.93% | ▼ −54.37% | — |
May 27, 2026 21w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.90% | — |
May 13, 2026 23w ago | EFFECT | $0.2950 $0.2950 | · 0.00% | ▲ +0.61% | — |
May 12, 2026 23w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.73% | — |
May 8, 2026 24w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −0.02% | — |
Apr 14, 2026 27w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −6.30% | — |
Apr 7, 2026 28w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −9.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers